NATCO receives emergency-use approval for Baricitinib tablets for COVID-19 treatment
Baricitinib, in combination with Remdesivir, is used for treatment of COVID-19-positive patients
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Natco Pharma
NATCO applies to CDSCO for EUA of Molnupiravir capsules to treat COVID-19
Pre-clinical data have shown that Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2…
NATCO gets tentative US FDA approval for Ibrutinib tablets
NATCO feels that it is eligible for 180 days of sole generic marketing exclusivity for all the strengths of the tablet dosage form…
Natco Pharma board okays acquiring 1 per cent in Canadian arm
Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary .
The…
NATCO ventures into Pheromone based tech for Integrated Pest Management
NATCO ventures into pheromone-based tech for integrated pest management
NATCO gets US FDA nod for Everolimus tablets
They are indicated in the treatment of breast cancer and a few other types of cancers
NATCO launches Brivaracetam tablets in India
Brivaracetam is indicated towards treatment of epilepsy.
Natco Pharma gets registration approval from CIB&RC for Chlorantraniliprole
Natco Pharma has received registration approval from Central Insecticide Board and Registration Committee for Chlorantraniliprole,…
NATCO launches Rivaroxaban¸ anticoagulant medication in India
Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market
NATCO gets US FDA approval for Pomalidomide capsules
It is indicated for the treatment of multiple myeloma